
protein kinase inhibitorIndian prescription status not found in lists checkedJan Aushadhi listed
Sunitinib
सुनिटिनिब
This page covers the capsules form only, as described in the EU product information. Other forms of sunitinib sold in India may differ.
Sunitinib is an anticancer protein kinase inhibitor taken as capsules. The EU product information covers adults with GIST after imatinib, advanced kidney cancer and pancreatic neuroendocrine tumours. Serious bleeding, heart and liver effects can occur, so specialist supervision is needed.
- Generic name
- Sunitinib
- Used for
- Treating GIST after imatinib, advanced kidney cancer and pancreatic neuroendocrine tumours in adults (EU label).
- Label used
- EU product information (EMA EPAR sunitinib-accord), retrieved 2026-10-15
- Prescription status (India)
- Not found in the Schedule H/H1/X/G lists we checked
- On NLEM 2022
- Not found in the list we checked
- NPPA price ceiling
- Not listed in the lists we checked
More facts
- Jan Aushadhi
- Listed (2 product rows)
- Banned combinations
- None found in the list we checked
Compiled from official drug labels and Indian government sources. Always follow your doctor's or pharmacist's advice.
Safety at a glance
- AlcoholNot mentioned in label text
- PregnancyAvoid, per label textSee wording
- BreastfeedingCaution in label textSee wording
- DrivingNot mentioned in label text
- KidneyCaution in label textSee wording
- LiverNot mentioned in label text
Taken only from the label text cited on this page. "Not mentioned" does not mean safe. Ask your doctor or pharmacist.
What is sunitinib used for?
This page uses EU product information (EMA) for Sunitinib Accord capsules. The label describes use in adults with unresectable or metastatic GIST after failure of imatinib, advanced or metastatic renal cell carcinoma, and unresectable or metastatic well-differentiated pancreatic neuroendocrine tumours with progression.
- GIST after imatinib resistance or intolerance
- Advanced or metastatic renal cell carcinoma
- Pancreatic neuroendocrine tumours with progression
It is a cancer medicine for GIST, kidney cancer and pancreatic neuroendocrine tumours.
Source1
How does sunitinib work?
Sunitinib blocks multiple receptor tyrosine kinases involved in tumour growth, new blood vessel formation and spread. These include PDGF, VEGF, KIT, FLT3, CSF-1R and RET receptors.
Its main metabolite has similar potency.
It blocks several signals that help tumours grow and form blood vessels.
Source1
How is sunitinib usually taken?
This page covers the capsules label only (route: ). Dosing for other forms differs, and the prescriber decides which one you use.
This is label-level information, not personal advice. Indian pack labels may differ, and your prescriber's instruction always comes first.
This page covers the oral capsule. The label says treatment should be started by a physician experienced with anticancer agents. For GIST and kidney cancer the label describes 50 mg once daily for 4 weeks, then 2 weeks off, as a 6-week cycle. For pancreatic tumours it describes 37.5 mg once daily without a scheduled rest period.
Dose changes are described in 12.5 mg steps based on tolerability, with limits above and below. Strong CYP3A4 inducers or inhibitors should be avoided, and if not possible the dose may need to be raised or lowered with careful monitoring.
- Specialist-started anticancer treatment
- 4 weeks on, 2 weeks off for GIST and kidney cancer
- Continuous daily dosing for pancreatic tumours
- Dose steps based on tolerability
The label describes specialist-led daily capsules, with a rest period in some cancers and dose steps for tolerability.
Source1
What are the side effects of sunitinib?
Common
- Low thyroid function may develop, and low blood counts are among the most common effects. Many symptoms may diminish as treatment continues.
- Reduced appetite and taste change
- High blood pressure
- Diarrhoea, nausea, vomiting, mouth sores
- Skin discolouration and hand-foot syndrome
- Low blood counts and low thyroid function
Serious: get help
- The most serious effects, some fatal, include renal failure, heart failure, pulmonary embolism, gut perforation and bleeding. Common effects include reduced appetite, taste change, high blood pressure, fatigue, diarrhoea, nausea, mouth sores, indigestion, vomiting, skin discolouration and hand-foot syndrome.
Common effects include tiredness, stomach upset, high blood pressure and skin changes; serious bleeding and heart effects can occur.
Source1
Who should be careful with sunitinib?
It is contraindicated with hypersensitivity to the active substance or excipients. The label warns of bleeding including tumour bleeding, severe skin reactions such as SJS and TEN, and skin or hair depigmentation. If SJS or TEN is confirmed, treatment must not be restarted.
Women of childbearing potential should use effective contraception and avoid pregnancy. The label says it should not be used during pregnancy unless the potential benefit justifies the risk to the foetus. Animal studies showed reproductive toxicity including malformations.
- Bleeding risk including tumour bleeding
- Severe skin reactions: stop if SJS or TEN
- Avoid pregnancy; use effective contraception
- Avoid strong CYP3A4 inhibitors and inducers
- Contraindicated if hypersensitive
It can cause serious bleeding and skin reactions, and pregnancy must be avoided.
Source1
What medicines interact with sunitinib?
- Strong CYP3A4 inhibitors: avoid or reduce dose
- Strong CYP3A4 inducers: avoid
- Grapefruit juice: may raise levels
- Strong CYP3A4 inhibitors such as ketoconazole, ritonavir, itraconazole, erythromycin, clarithromycin and grapefruit juice may raise sunitinib levels and should be avoided or the dose reduced.
- Strong CYP3A4 inducers such as rifampicin may lower levels and should be avoided.
- Interaction studies were only performed in adults.
No match in this label text. Ask your pharmacist about any medicine you take.
Drugs and grapefruit that change CYP3A4 activity can raise or lower its levels.
Source1
How should sunitinib be stored?
The label text we reviewed gives no storage temperature for this product.
Follow the storage line on your own pack, and keep medicines out of the reach of children.
Follow the storage instructions on your pack.
Source1
Is sunitinib a prescription medicine in India?
We did not find sunitinib in the Drugs Rules 1945 Schedule H, H1, X or G rows we checked, so we cannot state its Indian prescription status from our lists. Ask your pharmacist or doctor.
We did not find sunitinib on the National List of Essential Medicines 2022 in the list we checked.
The Jan Aushadhi (PMBJP) list we checked has 2 product rows that mention sunitinib. We did not capture prices for them.
We did not find sunitinib in the Schedule H, H1, X or G rows we checked, not found on NLEM 2022.
Source2
What is the price ceiling for sunitinib?
Jan Aushadhi lists sunitinib products including Sunitinib Capsules 12.5mg 12.5mg; Sunitinib Capsules 25mg 25mg. We have not shown a price for them. Check the pack and the seller for the actual price.
NPPA lists per-unit ceilings where a formulation is scheduled. Check the pack and seller.
Source2
Frequently asked questions
Can I drink alcohol while taking sunitinib?
The label we reviewed does not say. Ask your doctor or pharmacist.
Source1
Is sunitinib safe in pregnancy and breastfeeding?
The label says it should not be used in pregnancy unless the benefit justifies the risk to the foetus, and effective contraception is advised. Ask your doctor or pharmacist about breastfeeding.
Source1
Should sunitinib be taken with food?
The label advises avoiding grapefruit juice because it may raise levels. It does not otherwise say here. Ask your doctor or pharmacist.
Source1
Can sunitinib affect driving or alertness?
The label we reviewed does not say. Ask your doctor or pharmacist.
Source1
Can children or older adults take sunitinib?
The label we reviewed covers adult use only. Ask your doctor or pharmacist about older adults or children.
Source1
Is sunitinib on the NLEM and Jan Aushadhi list?
We did not find it on NLEM 2022. Yes, several sunitinib products are in the Jan Aushadhi list we checked.
Source2
Sources
- 1EMA European Public Assessment Report: product information (EU) (sunitinib-accord) Open source · 2026-10-15
- 2PMBJP (Jan Aushadhi) product list (p77:sno1682) Open source · 2026-10-15
Compiled by software from the sources above and checked by automated rules. Last checked: 2026-10-15 · How we use sources · Report a correction
This information is educational and is not a substitute for advice from your doctor or pharmacist. It does not tell you what dose you personally should take. In an emergency call 112.